Icatibant

Introduction Overview

Generic Name

icatibant

Brand Name

Firazyr

Dosage Form

Injection for subcutaneous use (single-dose prefilled syringe 30 mg/3 mL)

Drug Class

Hereditary angioedema agents; Bradykinin B2 receptor antagonists

Pharmacokinetics

Absorption:
Icatibant, the active component of Firazyr, is administered via subcutaneous injection specifically into the abdominal area. This route ensures rapid systemic absorption, achieving peak plasma concentrations generally within 30 minutes to 1 hour after dosing. The subcutaneous administration allows for efficient bioavailability, though exact absolute bioavailability figures are not extensively documented. Local enzymatic activity and regional blood flow at the injection site may influence absorption kinetics. Clinical trials have shown consistent pharmacodynamic effects correlating with this rapid absorption, facilitating prompt relief during acute hereditary angioedema (HAE) attacks.

Distribution:
Once absorbed systemically, icatibant displays a moderate distribution volume, indicating distribution beyond plasma into extracellular spaces. It has high protein binding affinity, primarily associating with plasma proteins, which modulates its free active fraction. These characteristics confirm that icatibant effectively reaches its target tissues, including vascular endothelial cells where B2 receptors are located. The drug’s distribution is facilitated by its physicochemical properties, with limited penetration into erythrocytes and no significant accumulation in adipose tissue. Given HAE primarily involves vascular leakage and swelling, the distribution profile allows for targeted action at sites of bradykinin-mediated inflammation.

Metabolism:
Icatibant undergoes metabolism predominantly through proteolytic cleavage by endopeptidases and exopeptidases, resulting in inactive peptide fragments. Unlike many small molecule drugs, it is not significantly metabolized via cytochrome P450 enzymatic pathways, minimizing the risk of CYP-mediated drug-drug interactions. The metabolic pathways largely involve non-CYP proteolytic breakdown in plasma and tissues, which ensures predictable metabolism regardless of hepatic function. This metabolic route emphasizes its peptide nature and contributes to its relatively short duration of action, necessitating dosing only during acute attacks.

Elimination:
The elimination of icatibant consists primarily of renal clearance of its inactive peptide metabolites rather than the intact molecule. The parent compound has a half-life estimated to be approximately 1 to 2 hours, allowing rapid offset of pharmacologic effects. Renal excretion dominates elimination, with minor contributions from other pathways due to proteolytic metabolism. This clearance profile supports flexible dosing up to three injections in 24 hours during acute attacks without concerns for accumulation. Patients with severe renal impairment have not been extensively studied, but given peptide metabolism, dose adjustment is generally not required. The rapid elimination is integral to its safety and efficacy in acute management of HAE.

Dosage Forms

Available Dosage Forms:
Firazyr is supplied exclusively as a single-dose prefilled syringe containing 30 mg of icatibant acetate in 3 mL solution, corresponding to a concentration of 10 mg/mL. This ready-to-use subcutaneous injection is designed for self-administration or administration by a caregiver during acute hereditary angioedema attacks.

Dosages for Adults and Adolescents:
The recommended dose for acute HAE attacks in adults (18 years and older) is 30 mg administered subcutaneously in the abdominal area. If symptoms persist or recur, up to two additional injections may be given at intervals of no less than 6 hours, with a maximum total of 90 mg (three injections) within 24 hours. Firazyr's dosing schedule reflects clinical trial data demonstrating rapid symptom relief while mitigating risks of overdose or adverse events.

Specific Patient Populations:
Firazyr safety and efficacy have not been established in pediatric patients under 18 years old. Use in older adults does not typically require dose adjustment, but increased sensitivity to adverse effects has been noted. In pregnant or breastfeeding women, there is limited data on safety; therefore, Firazyr should be used only if clearly needed. Renal or hepatic impairment does not require dose adjustment due to the drug's pharmacokinetic profile but warrants clinical monitoring. Firazyr's self-administration design facilitates use in outpatient settings, critical for timely intervention during acute attacks.

Mechanism Of Action

Firazyr (icatibant) acts as a selective antagonist of the bradykinin B2 receptor, a G protein-coupled receptor expressed on endothelial cells and various other tissues. During hereditary angioedema attacks, excessive bradykinin generation leads to activation of these receptors, causing vasodilation, increased vascular permeability, and subsequent angioedema. Icatibant binds competitively and with high affinity to B2 receptors, effectively blocking bradykinin from binding and activating these receptors.

On a cellular level, preventing bradykinin-B2 receptor interaction inhibits downstream signaling pathways that mediate the release of nitric oxide and prostacyclin, molecules responsible for vascular smooth muscle relaxation and increased permeability. This blockade suppresses the cascade leading to swelling, pain, and inflammation characteristic of HAE attacks. Firazyr’s rapid receptor binding ensures early interruption of pathological processes.

From a biochemical perspective, by targeting the B2 receptor rather than the ligand itself, Firazyr circumvents variability in bradykinin production and enzymatic degradation. This receptor-focused mechanism offers specificity and potency with a favorable safety profile. Clinical studies underscore its effectiveness with symptom relief typically observed within 2 to 2.5 hours post-injection, affirming the critical role of bradykinin B2 receptor antagonism in managing HAE.

Comparatively, while other HAE treatments include C1 esterase inhibitors or kallikrein inhibitors, Firazyr's mode of B2 receptor blockade offers an alternative mechanism directly intercepting bradykinin’s effects at the receptor level. This distinction allows its use as an acute rescue therapy, particularly valuable when plasma-derived or recombinant C1-INH products are unavailable or contraindicated. Ongoing research continues to explore the receptor pharmacodynamics and potential benefits in related pathophysiological conditions.

Pharmacological Actions

Selective antagonism of bradykinin B2 receptors to prevent bradykinin-mediated vascular permeability.
Rapid interruption of inflammatory mediator signaling in hereditary angioedema acute attacks.
Reduction of vasodilation and edema by inhibiting nitric oxide and prostacyclin release.
High-affinity competitive receptor binding with minimal off-target effects.
Peptide-based pharmacology allowing predictable metabolism and elimination.
Non-CYP mediated metabolism reducing potential for drug-drug interactions.
Facilitates rapid symptom relief typically within 2 to 2.5 hours post-administration.
Enables outpatient self-administered treatment for acute attacks of HAE.
Does not interfere with coagulation pathways, thus minimizing bleeding risk.
Demonstrated efficacy in Phase 3 clinical trials with over 88% of attacks resolved after a single dose.
Utilized as an alternative treatment option for patients intolerant or refractory to C1 esterase inhibitors.
Compatible with repeated dosing up to three times in 24 hours when necessary.
Acts directly at the receptor level, providing immediate receptor blockade without needing to reduce bradykinin synthesis.
Protein-based therapeutic with minimal immunogenicity reported in clinical use.
Contributes to reduction in hospitalization time by enabling self-care of acute attacks.

Therapeutic Or Clinical Uses

Treatment of acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older.
Rapid relief of swelling and pain associated with HAE attacks caused by excess bradykinin.
Management of subcutaneous angioedema involving the face, extremities, abdomen, or genitalia.
Treatment of potentially life-threatening laryngeal attacks to prevent airway obstruction.
Alternate acute therapy for patients unable to tolerate or access C1 esterase inhibitors.
Option for self-administration in outpatient and emergency settings to improve response time.
Use in repeated dosing up to three injections within 24 hours for unresolved or recurrent attacks.
Reduces need for rescue medications in a majority of HAE attack cases.
Shortens duration and severity of acute HAE symptoms, enhancing quality of life.
Supports individualized treatment plans as part of comprehensive HAE management.
Facilitates rapid intervention minimizing progression of angioedema episodes.
Recommended in treatment-guidelines as a first-line acute therapeutic agent for HAE attacks.
Useful for adult patients with known diagnosis of HAE types I and II involving C1-INH deficiency or dysfunction.
May be utilized in emergency departments to promptly manage acute swelling episodes.
Potential investigational use in bradykinin-mediated angioedema beyond hereditary forms.

Side Or Adverse Effects

Injection site reactions including redness, pain, irritation, and swelling.
Fever occurring as a mild systemic inflammatory response post-injection.
Elevated levels of hepatic transaminases indicating transient liver enzyme changes.
Dizziness, possibly related to hypotensive episodes or central nervous system effects.
Rash presenting as mild to moderate dermatologic reactions during treatment.
Allergic reactions ranging from mild hypersensitivity to rare anaphylactic symptoms.
Potential exacerbation of angioedema symptoms if administered improperly or too frequently.
Fatigue and somnolence noted in some patients following injection.
Nausea and gastrointestinal discomfort reported infrequently.
Localized bruising or hematoma at the injection site.
Rare occurrences of laryngeal edema necessitating emergency medical intervention.
Transient hypotension due to vasodilation blockade during acute attack resolution.
Injection site infection risk if aseptic technique is not maintained during administration.
Possible development of antibodies to icatibant with long-term use, though clinical significance is unclear.
Headache as a nonspecific neurological adverse effect during treatment.

Precautions

Do not exceed three injections within a 24-hour period to avoid overdose and adverse effects.
Always seek immediate medical attention if experiencing a laryngeal attack, even after injection.
Ensure proper training in subcutaneous self-administration technique prior to use.
Use cautiously in patients with known hypersensitivity to icatibant or any formulation components.
Patients with liver enzyme elevations should be monitored during treatment.
Advise avoidance of driving or operating machinery if dizziness or somnolence occur.
Use with caution in elderly patients due to increased susceptibility to adverse effects.
Pregnancy and breastfeeding safety have not been established; use only if clearly needed.
Maintain aseptic technique when preparing and administering injections to prevent infection.
Inform patients about signs of allergic reactions and necessity to seek urgent care if they occur.
Do not use in pediatric patients under 18 years due to insufficient safety and efficacy data.
Monitor for rebound or recurrence of symptoms requiring subsequent dosing.
Patients should report any persistent or worsening side effects to healthcare providers promptly.
Be aware of the potential overlap of allergic symptoms and hereditary angioedema manifestations.
Store prefilled syringes properly to maintain drug stability and effectiveness.

Warnings

Risk of life-threatening laryngeal attacks requiring immediate emergency care despite treatment.
Potential for severe allergic reactions including anaphylaxis necessitating medical intervention.
Do not use more than three doses within any 24-hour period to prevent toxicity.
Symptom worsening or lack of improvement demands urgent reassessment by healthcare professionals.
Not established safe for use in pediatric population under 18 years old.
May cause drowsiness and dizziness; caution advised when driving or operating heavy machinery.
Injection site reactions common but usually mild; severe local reactions should be evaluated.
Drug interactions may occur; disclose all medications to healthcare provider before use.
Inadequate response to Firazyr may necessitate alternative or adjunctive therapies.
Use caution in patients with hepatic impairment as safety data are limited.
Ensure patients or caregivers are educated on recognizing severe adverse reactions and appropriate responses.
Handling and disposal instructions must be followed to prevent injury and contamination.
Do not inject into areas that are bruised, swollen, scarred, or painful to avoid complication.
Emergency medical intervention must follow use in all cases of laryngeal edema.
Drug is not a preventative treatment but is intended exclusively for acute management.

Contraindication

Known hypersensitivity or allergy to icatibant or any ingredient in the formulation.
Previous severe allergic reaction to Firazyr or related agents.
Not indicated for use in pediatric patients under 18 years of age due to lack of safety data.
Contraindicated in patients with conditions or infections where subcutaneous injection is contraindicated.
Should not be used if the solution is cloudy, discolored, or contains particulate matter.
Use is contraindicated if administration guidelines cannot be safely followed (e.g., inability to self-inject).
Avoid if there is active infection or inflammation at the proposed injection site.
Contraindicated in individuals with known allergy to latex or needle components if applicable.
Use avoided in patients with hypersensitivity to any preservatives or excipients present.
Not suitable as prophylactic therapy; contraindicated if mistakenly used for prevention of HAE.
Should not be combined with other bradykinin receptor antagonists due to additive effects.
Avoid use during acute hypersensitivity reactions unrelated to HAE as it may complicate clinical picture.
Contraindicated in conditions where suppression of bradykinin could exacerbate underlying disorders.
Injection contraindications include severe thrombocytopenia or bleeding disorders at the injection site.
Not recommended for treatment of angioedema not mediated by C1-INH deficiency or bradykinin pathways.

Drug Interactions

Potential interactions with concomitant heart or blood pressure medications; monitor blood pressure closely.
Minimal cytochrome P450 interactions due to non-CYP metabolism; lowers risk of metabolic drug-drug interactions.
Caution with drugs that alter proteolytic enzymes potentially affecting icatibant metabolism.
Interaction potential with other hereditary angioedema agents like C1 esterase inhibitors or kallikrein inhibitors necessitates clinical supervision.
Co-administration with ACE inhibitors may alter bradykinin levels but no direct counteraction reported.
Concurrent use with medications causing dizziness or CNS depression may enhance these adverse effects.
Limited interaction with over-the-counter drugs, vitamins, or herbal products but all should be disclosed.
No significant interactions with anticoagulants or antiplatelet agents reported.
Intrinsic peptide nature limits interaction via common pharmacokinetic pathways.
Clinical monitoring advised when combining with immunomodulatory or biologic therapies.
No known interactions with vaccines but data are limited.
Potential additive allergic or hypersensitivity reactions if combined with other immunogenic agents.
Interaction with vasodilators may potentiate hypotensive effects; monitor blood pressure when co-administered.
Drug interaction profiles recommend thorough patient medication review before initiation.
No evidence of interactions affecting fertility or contraceptive efficacy.

Preparations Of The Drug

Firazyr is available as a sterile, non-pyrogenic, aqueous solution in a single-dose prefilled syringe.
Each prefilled syringe containing 3 mL solution delivers 30 mg icatibant acetate at 10 mg/mL concentration.
Formulated with inactive ingredients including sodium chloride (isotonicity reagent), glacial acetic acid, sodium hydroxide (pH adjusters), and purified water.
Supplied with a needle and needle cap for subcutaneous injection, designed for ease of use by patients or caregivers.
Packaged individually in cartons with Instructions for Use outlining safe self-administration steps.
Storage recommendations include refrigeration or room temperature maintenance, avoiding freeze-thaw cycles.
Designed for single use only; any unused portion must be discarded to ensure sterility and dosage accuracy.
Manufactured by Shire Orphan Therapies GmbH and distributed by Takeda Pharmaceuticals America, Inc.
Acidic pH adjusted for optimal icatibant stability and bioavailability upon subcutaneous administration.
No preservatives or antimicrobial agents included, necessitating strict aseptic technique during handling.
Prefilled syringes equipped with tamper-evident packaging for patient safety.
Disposal guidelines require use of FDA-cleared sharps containers conforming to local regulatory standards.
Visual inspection before use is mandatory to confirm clarity and absence of particulates.
The formulation is specifically optimized for rapid absorption and minimal local irritation.
No oral or alternative delivery forms currently available; therapy limited to subcutaneous injection.